Trial Profile
Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Dec 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Pegfilgrastim; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 17 Aug 2023 Planned End Date changed from 3 Jul 2024 to 11 Nov 2024.
- 20 Jul 2023 Planned End Date changed from 3 Jun 2023 to 3 Jul 2024.
- 13 Feb 2023 Planned End Date changed from 31 Dec 2022 to 3 Jun 2023.